๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for RAS Mutation

Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC NCT06162221Phase 1, Phase 298 sites๐Ÿ“ Gilbert๐Ÿ“ Duarte๐Ÿ“ Irvine Revolution Medicines, Inc. ยท Tests: RMC-6291, RMC-6236, Pembrolizumab, Cisplatin, Carboplatin A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies NCT04678648Phase 13 sites๐Ÿ“ Los Angeles๐Ÿ“ Denver๐Ÿ“ Nashville RasCal Therapeutics, Inc. ยท Tests: RSC-1255 Dose Escalation, RSC-1255 Dose Expansion Development of a cfDNA 5mC/5hmC-based Biomarker Panel to Predict Targeted Therapy Efficacy in mCRC NCT07224841n/a1 site๐Ÿ“ Duarte City of Hope Medical Center ยท Tests: cfDNA 5mC/5hmC Sequencing (EpiDRIVE Discovery Phase), EpiDRIVE Assay (Targeted Sequencing / qPCR Validation) FOLFOX Via HAI Plus Intravenous Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Without Bevacizumab in Initially Unresectable RAS-mutated CRLM Patients NCT05727163Phase 21 site๐Ÿ“ Guangzhou Sun Yat-sen University ยท Tests: Dexamethasone, Anisodamine, Oxaliplatin, Leucovorin, Fluorouracil Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma NCT07805954Phase 35 sites๐Ÿ“ Phoenix๐Ÿ“ Scottsdale๐Ÿ“ Jacksonville Revolution Medicines, Inc. ยท Tests: daraxonrasib, gemcitabine, nab-paclitaxel, zoldonrasib MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies NCT05735717Phase 21 site๐Ÿ“ Minneapolis Masonic Cancer Center, University of Minnesota ยท Tests: Fludarabine, Busulfan, Melphalan, Rituximab, Levetiracetam A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer NCT07644559Phase 238 sites๐Ÿ“ Los Angeles๐Ÿ“ Los Angeles๐Ÿ“ Los Angeles Verastem, Inc. ยท Tests: VS-7375, cetuximab (or panitumumab if ฮฑ-gal IgE+ or cetuximab reaction) PAS-004 in Patients With Advanced Solid Tumors NCT06299839Phase 17 sites๐Ÿ“ Austin๐Ÿ“ Irving๐Ÿ“ San Antonio Pasithea Therapeutics Corp. ยท Tests: PAS-004 Capsules, PAS-004 Tablets Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS NCT05379985Phase 1, Phase 221 sites๐Ÿ“ Orange๐Ÿ“ Santa Monica๐Ÿ“ Tampa Revolution Medicines, Inc. ยท Tests: RMC-6236 A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors NCT06326411Phase 123 sites๐Ÿ“ San Francisco๐Ÿ“ Westwood, Los Angeles๐Ÿ“ Denver Nested Therapeutics, Inc ยท Tests: NST-628 FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer NCT07446322Phase 219 sites๐Ÿ“ Homewood๐Ÿ“ Beverly Hills๐Ÿ“ Encino Oncolytics Biotech ยท Tests: Bevacizumab, FOLFIRI, Pelareorep Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients NCT03190941Phase 1, Phase 21 site๐Ÿ“ Bethesda National Cancer Institute (NCI) ยท Tests: Cyclophosphamide, Fludarabine, Anti-KRAS G12V mTCR PBL, Aldesleukin Cadonilimab in Combination With Bevacizumab and FOLFOX Regimen for the First-Line Treatment of Advanced Unresectable MSS-Type, RAS-Mutated Metastatic Colorectal Cancer NCT06218810Phase 21 site๐Ÿ“ Shanghai Fudan University ยท Tests: Cadonilimab + bevacizumab + FOLFOX A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation NCT07678593Phase 1, Phase 217 sites๐Ÿ“ Concord๐Ÿ“ North Ryde๐Ÿ“ Woodville South Genfleet Therapeutics (Shanghai) Inc. ยท Tests: GFH276, Cetuximab, Nab paclitaxel, Gemcitabine, Fluorouracil Study of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS NCT07435038Phase 1, Phase 27 sites๐Ÿ“ Blacktown๐Ÿ“ Randwick๐Ÿ“ Sydney Betta Pharmaceuticals Co., Ltd. ยท Tests: BPI-572270 Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies NCT05786924Phase 1, Phase 249 sites๐Ÿ“ Gilbert๐Ÿ“ Los Angeles๐Ÿ“ Los Angeles Institut de Recherches Internationales Servier ยท Tests: S241656, FOLFOX6/FOLFOX7, FOLFIRI, Cetuximab, Panitumumab Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 ) NCT07621718Phase 319 sites๐Ÿ“ Phoenix๐Ÿ“ Tucson๐Ÿ“ New Haven Revolution Medicines, Inc. ยท Tests: Zoldonrasib, Placebo, Oxaliplatin, Leucovorin (Calcium Folinate), 5-Fluorouracil Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors NCT07349537Phase 19 sites๐Ÿ“ New Haven๐Ÿ“ Baltimore๐Ÿ“ Boston Revolution Medicines, Inc. ยท Tests: RMC-5127, daraxonrasib, cetuximab RASopathy Biorepository NCT04395495n/a1 site๐Ÿ“ Cincinnati Children's Hospital Medical Center, Cincinnati Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors NCT03454035Phase 11 site๐Ÿ“ Chapel Hill UNC Lineberger Comprehensive Cancer Center ยท Tests: Ulixertinib, Palbociclib Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors NCT07397338Phase 1, Phase 29 sites๐Ÿ“ Los Angeles๐Ÿ“ Norwich๐Ÿ“ Saint Paul Revolution Medicines, Inc. ยท Tests: Daraxonrasib, Elironrasib, Zoldonrasib, Ivonescimab, Carboplatin/Cisplatin + Pemetrexed (Dose Expansion Only) Other Oncogene Mutations for Anti-EGFR Efficacy in Patients With Left-sided RAS-wild Type Metastatic Colorectal Cancer NCT06226857Phase 33 sites๐Ÿ“ Moscow๐Ÿ“ Moscow๐Ÿ“ Reutov City Clinical Oncology Hospital No 1 ยท Tests: Cetuximab Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301) NCT06881784Phase 3158 sites๐Ÿ“ Birmingham๐Ÿ“ Long Beach๐Ÿ“ New Haven Revolution Medicines, Inc. ยท Tests: daraxonrasib, docetaxel STREAM-2: Second-line Treatment With REgorafenib in Advanced RAS-Mutant Colorectal Cancer NCT07213570Phase 21 site๐Ÿ“ Naples National Cancer Institute, Naples ยท Tests: standard second line treatment, at discretion of the investigator, Regorafenib (BAY73-4506) Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC) NCT07252232Phase 386 sites๐Ÿ“ Birmingham๐Ÿ“ Phoenix๐Ÿ“ Scottsdale Revolution Medicines, Inc. ยท Tests: daraxonrasib Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients NCT06922591Phase 1, Phase 218 sites๐Ÿ“ Scottsdale๐Ÿ“ Denver๐Ÿ“ Washington D.C. Tango Therapeutics, Inc. ยท Tests: TNG462, RMC-9805, RMC-6236, mFOLFIRINOX, gemcitabine/nab-paclitaxel CAnadian CAncers With Rare Molecular Alterations (CARMA) - Basket Real-world Observational Study (BROS) NCT04151342n/a27 sites๐Ÿ“ Calgary๐Ÿ“ Edmonton๐Ÿ“ Vancouver University Health Network, Toronto ยท Tests: Cancer treatment with tyrosine kinase inhibitors (TKIs) or other molecularly targeted therapeutic agents., Patient-repoโ€ฆ A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation NCT07458347Phase 19 sites๐Ÿ“ Los Angeles๐Ÿ“ Sarasota๐Ÿ“ Tampa Kestrel Therapeutics, Inc. ยท Tests: KST-6051, Gemcitabine/nab-paclitaxel, Cetuximab, Pembrolizumab, mFOLFOX6 Irinotecan Liposomes Combined with Cetuximab + Vermofenib in First-line Failure of Advanced Colorectal Cancer NCT06763029Phase 21 site๐Ÿ“ Shanghai Fudan University ยท Tests: Irinotecan liposomes combined with cetuximab + vermofenib Hematological Anomalies in Children With Rasopathy NCT04286360n/a14 sites๐Ÿ“ Angers๐Ÿ“ Caen๐Ÿ“ Lille Assistance Publique - Hรดpitaux de Paris
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy